Penumbra PEN R&D
R&D at other companies
Other financials
Where this comes from
Reported directly by Penumbra in its filing.
Tagged under the XBRL concept us-gaap:ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost.
The official record: Penumbra’s 10-Q, filed May 6, 2026, on SEC EDGAR. View the filing →
Ask your AI about Penumbra's r&d.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Penumbra's R&D?
- Penumbra (PEN) reported R&D of $22.38M in Q1 2026.
- How has Penumbra's R&D changed year-over-year?
- Penumbra's R&D increased by 1.4% year-over-year, from $22.08M to $22.38M.
- What is the long-term trend for Penumbra's R&D?
- Over 4 years (2021 to 2025), Penumbra's R&D has grown at a -3.7% compound annual growth rate (CAGR), from $104.55M to $89.77M.
- What does R&D mean?
- Spending dedicated to creating new products or improving existing ones.
- How do you interpret R&D?
- Increased spending signals a commitment to innovation and future product pipelines, while significant decreases may signal a shift in strategy or potential long-term stagnation.
- How does R&D compare across companies?
- Highly comparable among medical device peers; reflects the intensity of innovation cycles in the industry.